Home

Articles from Amicus Therapeutics, Inc.; Dimerix Limited

Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States
Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatmentof Focal Segmental Glomerulosclerosis (FSGS)
By Amicus Therapeutics, Inc.; Dimerix Limited · Via GlobeNewswire · April 30, 2025